Michael Gladstone

Michael is a partner at Atlas Ventures and focuses on building new therapeutics companies. Michael is a board member of Third Harmonic Bio, Day One Biopharmaceuticals, Pheon Therapeutics, and Versanis Bio. Michael was previously a board observer for Akero, AvroBio, Delinia (acquired by Celgene), Replimune, and Xilio Therapeutics.

Prior to joining Atlas in 2012, Michael worked at L.E.K. Consulting, where he focused on business development and corporate strategy for biopharma clients. Previously, Michael worked in the Viral Pathogenesis department of Beth Israel Deaconess Medical Center where he led research on HIV vaccines with Harvard Medical School Professor Norman Letvin.

Michael received an AB in biochemical sciences with highest honors from Harvard College, where he graduated magna cum laude and was awarded the Harvard College Scholarship and Herchel Smith Undergraduate Research Fellowship.